Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 29, 2007

Unigene Inks Supply Deal With Novartis

  • Unigene Laboratories will receive $2.5 million to supply Novartis with specified quantities of a bulk peptide necessary for development of its osteoporosis treatment.

    Unigene will develop a process for the peptide, and Novartis will have the opportunity to purchase additional quantities as necessary.

    In 2004, Novartis exclusively licensed Unigene's technology to manufacture another peptide, calcitonin, and it now runs the scaled-up process at its manufacturing facility in Kundl, Austria.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »